Insider Transactions in Q2 2025 at Ptc Therapeutics, Inc. (PTCT)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
883
-0.84%
|
$40,618
$46.02 P/Share
|
|
May 16
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
883
+0.84%
|
$22,075
$25.69 P/Share
|
|
May 15
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,929
-1.82%
|
$88,734
$46.18 P/Share
|
|
May 15
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,929
+1.79%
|
$48,225
$25.69 P/Share
|
|
Apr 22
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,804
-1.02%
|
$134,592
$48.74 P/Share
|
|
Apr 02
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
897
-1.17%
|
$41,262
$46.95 P/Share
|